Metformin Suppresses Metastatic Potential and Sensitizes Ovarian Cancer Cells to Chemotherapeutics
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27177779 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Megha J Pandya und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA. Hauptthemen laut MEDLINE: Metformin, Ovarian Neoplasms, Antineoplastic Agents. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, United States Department of Defense, University of Maryland, Baltimore.
Abstract (Originalsprache)
The failure of current therapeutics to elicit a durable response in metastatic ovarian cancer patients highlights the urgent need to develop more effective treatment strategies. In this study, we demonstrate that the anti-diabetic drug metformin exerts cytotoxic effects across a broad panel of ovarian cancer cell lines. Transcriptomic analyses revealed that, in addition to reducing cell viability and proliferation, metformin modulates pathways associated with metastatic progression, including cell migration, extracellular matrix remodeling, and cellular responses to chemotherapeutic agents. Consistent with these molecular changes, metformin significantly impaired ovarian cancer cell migration and invasion through Matrigel. Furthermore, metformin diminished the ability of ovarian cancer cells to form multicellular aggregates, a key property that facilitates successful metastatic dissemination within the peritoneal cavity. Although metformin produced only a modest increase in carboplatin sensitivity, systematic screening of FDA-approved drugs identified several agents whose efficacy was enhanced by metformin, including drugs not currently used to treat ovarian cancer. Collectively, these findings demonstrate that metformin suppresses metastatic phenotypes and enhances therapeutic vulnerability in ovarian cancer cells, supporting its potential repurposing as a combination therapy to improve treatment outcomes in ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA.
- University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore, MD 21201, USA.
ORCID-Profile: Megha J Pandya, Ayokunnumi Ogunsanya, Adedoyin Ajibade, Achuth Padmanabhan
Förderung
- NIH HHS
- United States Department of Defense
- University of Maryland, Baltimore
- Ovarian Cancer Alliance of Greater Cincinnati
- American Cancer Society
- NCATS NIH HHS
- NCI NIH HHS
- Department of Defense
Zitieren
APA
Pandya, M. J., Ogunsanya, A., Ajibade, A., & Padmanabhan, A. (2026). Metformin Suppresses Metastatic Potential and Sensitizes Ovarian Cancer Cells to Chemotherapeutics. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27177779
Vancouver
Pandya MJ, Ogunsanya A, Ajibade A, Padmanabhan A. Metformin Suppresses Metastatic Potential and Sensitizes Ovarian Cancer Cells to Chemotherapeutics. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27177779
BibTeX
@article{Pandya2026,
author = {Pandya, Megha J and Ogunsanya, Ayokunnumi and Ajibade, Adedoyin and Padmanabhan, Achuth},
title = {Metformin Suppresses Metastatic Potential and Sensitizes Ovarian Cancer Cells to Chemotherapeutics},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27177779}
}
EUVIMED